The groundbreaking ceremony for Phase I and the signing ceremony for Phase II of Kousai, a biotechnology company at the Zhongshan Life Science Park in Cuiheng New District, were held on December 25.

Founded in 2018, Kousai is a technology-driven enterprise that specializes in the research and development, production and sales of dendritic cell vaccines. It earned the recognition as a high-tech enterprise in 2022.

This time, Kousai has leased approximately 1,000 square meters on the second floor of Building 11, Phase I of the Zhongshan Life Science Park as its R&D base, and intends to lease approximately 11,000 square meters of a single factory building in Phase II of the park as its industrial production base.

Cheng Xiangguo, founder and COO of Kousai, said that the investment will not only be utilized to ensure the steady progress of project research and development, testing and clinical testing, but also for talent training and recruitment. This aims to enhance the overall strength of the company's R&D team and provide a robust guarantee for the success of the project.